PGEN
PRECIGEN, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.66
+4.31%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.45
From 52W high−22.20%
Volume4.14M
Market cap$2.38B
P/E (TTM)—
P/S (TTM)27.8x
Div yield—
Key dataOct 19, 2026
Open
$6.45
From 52W high
−22.20%
Volume
4.14M
Market cap
$2.38B
ValuationView details →
P/E (Fwd)
9.7x
EV/EBITDA
−17.0x
P/E (TTM)
—
RSI (14)
38.4
MomentumView details →
1D Return
+4.31%
YTD Return
+58.49%
SummaryUpdated Jun 1, 2026
Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company founded in 1998 and headquartered in Germantown, Maryland. Originally known as Intrexon Corporation, the company rebranded to Precigen in January 2020 to better reflect its focus on precision gene and cellular therapies. The company has evolved from a broader synthetic biology platform into a specialized developer of next-generation gene and cellular therapies, with particular emphasis on rare diseases and cancer treatments. Precigen has undergone significant strategic restructuring in recent years, streamlining operations to focus on its most promising therapeutic candidates while divesting non-core assets.
Similar companies
Latest newsMore news →
The United States Food and Drug Administration granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, which is used in its commercial product PAPZIMEOS.29d agoJeffrey B. Kindler, a director at Precigen, Inc., sold 185,000 shares of the company's common stock on August 26, 2026, for a total value of $1,376,400.52d agoPrecigen Inc. reported second-quarter net product revenue of $53.1 million for PAPZIMEOS, more than double the prior quarter, and achieved quarterly profitability.56d ago